Outlook Therapeutics has resubmitted its Biologics License Application to the FDA for ONS-5010/LYTENAVA™, a treatment for neovascular age-related macular degeneration (wet AMD). The FDA has recognized substantial evidence of effectiveness, requiring no additional trials, and assigned a Class 1 review with a decision expected within 60 days. If approved, ONS-5010 will be the first FDA-approved ophthalmic bevacizumab formulation, offering patients a new, standardized treatment option. The company is collaborating closely with the FDA to finalize product labeling and aims to provide wider access to this therapy.
Bitcoin miners are experiencing declining revenue as the network's hash rate and mining difficulty fall, reflecting a shift of miners into AI infrastructure. Despite this stress, miners are accumulating Bitcoin, with reserves increasing by 1%, signal...
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
